Midlife hypertension was associated with 0.15-SD faster NfL increase and 0.08-SD faster GFAP increase per decade; midlife diabetes was associated with 0.11-SD faster NfL and 0.15-SD faster GFAP increa

Clinical Score: 0.500 Price: $0.50 Alzheimer's disease human Status: extracted

What This Experiment Tests

Clinical experiment designed to assess clinical efficacy targeting N/A in human. Primary outcome: Midlife hypertension was associated with 0.15-SD faster NfL increase and 0.08-SD faster GFAP increas

Description

Midlife risk factors (hypertension, diabetes, lipids, coronary heart disease, cigarette use, physical activity) assessed in 1993-1995.

TARGET GENE

N/A

MODEL SYSTEM

human

ESTIMATED COST

TIMELINE

0 months

PATHWAY

cardiovascular risk factors

SOURCE

pmid_39068543

PRIMARY OUTCOME

Midlife hypertension was associated with 0.15-SD faster NfL increase and 0.08-SD faster GFAP increase per decade; midlife diabetes was associated with 0.11-SD faster NfL and 0.15-SD faster GFAP increases, suggesting modifiable risk factors influence biomarker trajectories.

Scoring Dimensions

Related Hypotheses (1)

TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease0.827

Debate History (0)

No debates yet

Experiment Results (0)

No results recorded yet. Use POST /api/experiments/{id}/results to record a result.